United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

The results came from a randomized, controlled trial of Pfizer's booster dose in more than 10,000 individuals 16 years of age and older.

Pfizer says its booster shot has 95.6% efficacy against COVID-19 amid the Delta variant

Pfizer Inc. PFE, +0.05% and German partner BioNTech SE BNTX, -4.90% said Thursday a late-stage trial of a 30 mg booster dose of their COVID-19 vaccine showed efficacy of 95.6% compared with those who received a placebo.

Pfizer and BioNTech say Phase 3 trial found booster dose of COVID vaccine had 95.6% efficacy against disease

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine in more than 10,000 individuals 16 years of age and older. In the trial, a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series restored vaccine protection against COVID

Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine

Comirnaty vaccination now involves between two and four separate treatments, a substantial increase on the initial two-dose vaccination schedule.

COVID Vaccine Is Not A Non-Event For Pfizer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) for routine use to help protect adults against invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine. Specifically, the ACIP voted to recommend the following: Adults 65 years of age or old

Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer's PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults

97% of US teens hospitalized with COVID-19 were unvaccinated in the cases the CDC studied for its analysis.

Pfizer's vaccine cuts the risk of COVID-19 hospitalization in teens by 93%, CDC analysis says

LONDON--(BUSINESS WIRE)--Less talk, more action: New report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040

Less Talk, More Action: New Report Sponsored by ViiV Healthcare Provides Roadmap to Achieve Health Equity by 2040

The study found 97% of those hospitalized were unvaccinated, including every patient who was placed in intensive care or died.

Pfizer's Covid Vaccine 93% Effective At Preventing Teen Hospitalizations, CDC Study Finds

Johnson & Johnson

Moderna

On Tuesday, it became clear that the FDA plans to allow for a “mix and match” approach to vaccine booster shots, allowing—as the Europeans have recommended—people who have been vaccinated against Covid-19 to get a booster shot made from different company than the company that gave them their first dose.  In case you suffer from any long Covid-related intellectual deterioration, this means, for example, you can get booster shot from Johnson & Johnson (J&J) or Pfizer even if your first dose was delivered into your arm courtesy of Moderna.

Which Vaccine Stock Will Benefit Most From FDA's "Mix And Match" Approval?

Pfizer's Covid vaccine is 93% effective at protecting against hospitalization in 12- to 18-year-olds, the CDC said in a small study released Tuesday.

CDC study shows Pfizer Covid vaccine is 93% effective against hospitalization in 12- to 18-year-olds

Pfizer CEO Albert Bourla revealed he personally received a COVID-19 vaccine booster recently and expects federal regulators to make booster shots more widely available in the United States.

Pfizer CEO says he's gotten a COVID vaccine booster shot and most of us will, too

The CHMP recommends approving Pfizer (PFE) JAK inhibitors abrocitinib and Xeljanz for the treatment of atopic dermatitis and active ankylosing spondylitis, respectively.

Pfizer (PFE) Gets CHMP Nod for JAK Inhibitor Abrocitinib

Pfizer reported 92% revenue growth for Q2 2021 and raised the high end of its full-year 2021 earnings guidance from $3.65 to $4.05 per share. While the blowout numbers are being driven by the company's COVID vaccine success, the market is underappreciating the quality, stability, and growth potential of Pfizer's overall portfolio.

Pfizer Is An Asymmetric Growth Opportunity

AstraZeneca

Two doses of either the vaccine made by Pfizer PFE, -0.43% and BioNTech [s:bntx] or Oxford-AstraZeneca AZN, +0.92% vaccines provided a similar level of protection to prior natural infection when the Delta variant was dominant, the U.K. Office of National Statistics said Monday. Vaccination significantly reduced the risk of people testing positive during both the Alpha-dominant period and the Delta-dominant period, but effectiveness was reduced in the Delta-dominant period compared with the Alpha-dominant period.

Pfizer and AstraZeneca vaccines were effective as prior infection, U.K. study finds

It depends mainly on the number of breakthrough cases of COVID-19.

Europe Recommends Pfizer Boosters for Ages 18 and Up: Could the U.S. Soon Follow?

Merck

Roche Holding AG

These big drugmakers could soon compete against each other with oral COVID-19 therapies.

3 COVID-19 Pill Stocks to Watch

Here's how the two big-pharma stocks stack up against each other.

Better COVID-19 Stock: Merck or Pfizer?

Pfizer Inc. (NYSE: PFE) shares have lagged the S&P 500 in 2021, generating a year-to-date total return of 16.6%. Pfizer has gotten plenty of headlines for its COVID-19 vaccine, but investors may be wondering just how much value is left in the pharma giant's stock?

Is Pfizer's Stock Overvalued Or Undervalued?

AbbVie

Abbott Labs

America First Multifamily Investors

Bristol-Myers

Annaly Capital

For high yield hunters, market corrections are an opportunity to enhance their income stream.

Make Money In Your Sleep: 3 Big Dividends To Buy Today

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the 100 mg and 200 mg doses of abrocitinib, an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for marketing authorization to treat moderate to severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. The CHMP also adopted a positive opinion recommending marketing

Pfizer's Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis

Pfizer has expanded its mRNA program into a new area.

Pfizer's Next mRNA Vaccine Candidate Goes Beyond COVID-19

Stitch Fix

Trade Desk

Here are three companies for long-term investors to consider this month.

3 Top Stocks Under $100

The bar could be lower for the FDA to authorize booster shots for J&J's COVID-19 vaccine.

Could Johnson & Johnson's Booster Opportunity Be Better Than Pfizer's and Moderna's?

Delta Air Lines

Goldman Sachs

J.B. Hunt Transport Services

Southwest Airlines

Prologis

The indexes had been trying to turn around a steep drop to the start of the week, and finally managed on Thursday.

Best Single Trading Day in Months for Dow, Nasdaq, S&P

Is (PFE) Outperforming Other Medical Stocks This Year?

News for Pfizer Stock (PFE)